arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Drugs Made In America Acquisition Corp.

DMAA

$10.88 0.00 (0.00%) at close

9 Visible periods

12 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Drugs Made In America Acquisition Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 1.5% ↘

FCF / Share —

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 4, 2026.

9-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$1.97M

↑ +57.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗
Net Income Growth YoY (%)	57.1% Excellent Excellent Year-over-year change in net income	57.1% Excellent Excellent Year-over-year change in net income	—	N/M	N/M	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗
FCF / Net Income (x)	-0.12x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.05x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.04x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	-0.20x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	—	3.13x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	2.09x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗
Return on Invested Capital (%)	1.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	1.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	22.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	2.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	1.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	3.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	—	95.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	217.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-0.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-0.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-0.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-0.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-0.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-0.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-26.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-322%)	-26.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-323%)	-2.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-124%)	-17.1% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	-17.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-246%)	-17.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-246%)	—	33.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+178%)	275.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+2197%)

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗
Net Debt (USD)	$-20.28K	$-14.89K	—	—	—	—	—	—	—

📊 What does each share earn? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗
Book Value per Share (USD)	$-0.69	$-0.69	$-0.68	$-0.70	$-0.68	$-0.68	$-0.02	—	—
Tangible Book Value per Share (USD)	$-0.69	$-0.69	$-0.68	$-0.70	$-0.68	$-0.68	$-0.02	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗
Working Capital (USD)	$-2.88M	$-477.28K	$-363.98K	$-428.42K	$-251.72K	$-276.35K	$-790.68K	—	—
Total Equity (USD)	$-7.41M	$-7.38M	$-7.26M	$-7.33M	$-7.15M	$-7.18M	$-244.84K	$-164.86K	$-19.93K

📋 What is driving earnings? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗
Net Income, GAAP (USD)	$1.97M	$1.97M	$212.96K	$1.25M	$1.25M	$1.25M	—	$-54.93K	$-54.93K
Operating Cash Flow (USD)	$-244.61K	$-91.25K	$-125.18K	$-56.11K	—	$-251.24K	—	$-172.16K	$-114.93K

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 2 years · 9 quarters

Drugs Made In America Acquisition Corp.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DMAA with peers